Golden Meditech Gains US OK for Houston T-Cell Processing Center

Golden Meditech of Hong Kong reported that Cellenkos, its Houston, Texas subsidiary, was granted Good Manufacturing Status by the FDA for a T-Cell processing facility. The facility processes cord blood-derived regulatory T-cells that will be tested as immune system suppressors in several autoimmune diseases. Last year, Golden Meditech formed a partnership with M.D. Anderson Hospital and a private investor to back Cellenkos and its processing facility. Previously, Golden Meditech was involved with China Cord Blood, a cord blood banking company, which it sold for $737 million in 2017. More details.... Stock Symbol: (HK: 00801) Share this with colleagues: // //